Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
26S proteasome non-ATPase regulatory subunit 13 (PSMD13) is a non-ATPase component of the 19S regulator "lid" in the 26S proteasome, a large multicatalytic complex responsible for the ATP-dependent degradation of ubiquitinated proteins via a non-lysosomal pathway in eukaryotic cells. This protein plays an essential role in protein quality control, homeostasis, and regulated protein turnover, with downstream effects on processes including the cell cycle, apoptosis, DNA repair, and inflammation. The proteasome’s malfunction or dysregulation, including altered PSMD13 function/expression, is implicated in the pathogenesis of cancer, neurodegenerative disorders, and inflammatory diseases. Although no drugs specifically target PSMD13 alone, proteasome inhibitors like bortezomib target the proteasome complex for anti-cancer and research purposes.
Inhibition of proteasome-mediated protein degradation, leading to accumulation of ubiquitinated proteins, induction of cell cycle arrest and apoptosis, reduction of inflammatory mediator production
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 26S proteasome non-ATPase regulatory subunit 13 (PSMD13).